There were 414 press releases posted in the last 24 hours and 401,783 in the last 365 days.
Please use this form to send email to PR contact of this press release:
Immunophotonics Announces 1st Patient Dosed in IP-IIO-622 Phase 1b/2a Clinical Trial in Advanced Solid Tumor Indications
TO:
Public Relations
Immunophotonics, Inc.